Subcellular differential expression of Ep-ICD in oral dysplasia and cancer is associated with disease progression and prognosis

about

Subcellular differential expression of Ep-ICD in oral dysplasia and cancer is associated with disease progression and prognosis

Item

http://www.wikidata.org/entity/Q36078946

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Subcellular differential expre ...... ease progression and prognosis

@ast

Subcellular differential expre ...... ease progression and prognosis

@en

type

Item

label

Subcellular differential expre ...... ease progression and prognosis

@ast

Subcellular differential expre ...... ease progression and prognosis

@en

prefLabel

Subcellular differential expre ...... ease progression and prognosis

@ast

Subcellular differential expre ...... ease progression and prognosis

@en

P1476

Subcellular differential expre ...... ease progression and prognosis

@en

P2093

Christina MacMillan

http://www.w3.org/2001/XMLSchema#string

Ian J Witterick

http://www.w3.org/2001/XMLSchema#string

Iona Leong

http://www.w3.org/2001/XMLSchema#string

Paul G Walfish

http://www.w3.org/2001/XMLSchema#string

Raj Thani Somasundaram

http://www.w3.org/2001/XMLSchema#string

Ranju Ralhan

http://www.w3.org/2001/XMLSchema#string

P2860

Nuclear signalling by tumour-associated antigen EpCAM

EpCAM (CD326) finding its role in cancer

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Frequent EpCam protein expression in human carcinomas

The emerging role of EpCAM in cancer and stem cell signaling

EpCAM in carcinogenesis: the good, the bad or the ugly

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion.

Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).

EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis

P2888

s12885-016-2507-7

P304

486

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-016-2507-7

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jatinder Kaur

P577

2016-07-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1053209154

http://www.w3.org/2001/XMLSchema#string

P698

27421772

http://www.w3.org/2001/XMLSchema#string

P932

4947324

http://www.w3.org/2001/XMLSchema#string